1. The anthracyclines: When good things go bad

   • Giorgio Minotti
   • Narine Sarvazyan

   Editorial 03 May 2007 Pages: 53 - 55

   

2. Role of anthracyclines in the era of targeted therapy

   • Hernán Cortés-Funes
   • Cyntia Coronado

   OriginalPaper 25 April 2007 Pages: 56 - 60

   

3. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy

   • Christian Zuppinger
   • Francesco Timolati
   • Thomas M. Suter

   OriginalPaper 26 April 2007 Pages: 61 - 66

4. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

   • Luca Gianni
   • Emanuela Salvatorelli
   • Giorgio Minotti

   OriginalPaper 19 April 2007 Pages: 67 - 71

   

5. Cardiac safety of liposomal anthracyclines

   • Gerald Batist

   OriginalPaper 25 April 2007 Pages: 72 - 74

6. Ongoing phase I and II studies of novel anthracyclines

   • Cristiana Sessa
   • Olga Valota
   • Cristina Geroni

   OriginalPaper 22 May 2007 Pages: 75 - 79

   

7. An introduction to the metabolic determinants of anthracycline cardiotoxicity

   • Pierantonio Menna
   • Stefania Recalcati
   • Giorgio Minotti

   OriginalPaper 25 April 2007 Pages: 80 - 85

   

8. Anthracycline-induced phospholipase A₂ inhibition

   • Luther Swift
   • Jane McHowat
   • Narine Sarvazyan

   OriginalPaper 19 April 2007 Pages: 86 - 91

   

9. Iron signaling and oxidant damage

   • Balaraman Kalyanaraman

   Original Paper 03 May 2007 Pages: 92 - 94

   

10. Antioxidant defense against anthracycline cardiotoxicity by metallothionein

    • Y. James Kang

    OriginalPaper 19 April 2007 Pages: 95 - 100

11. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

    • Kendall B. Wallace

    OriginalPaper 19 April 2007 Pages: 101 - 107

    

12. Role of mtDNA lesions in anthracycline cardiotoxicity

    • Dirk Lebrecht
    • Ulrich A. Walker

    OriginalPaper 25 April 2007 Pages: 108 - 113

    

13. Molecular and cellular mechanisms of anthracycline cardiotoxicity

    • Billy Chen
    • Xuyang Peng
    • Douglas B. Sawyer

    OriginalPaper 03 May 2007 Pages: 114 - 121

    

14. Anthracycline cardiotoxicity in long-term survivors of childhood cancer

    • Rebecca E. Scully
    • Steven E. Lipshultz

    OriginalPaper 19 April 2007 Pages: 122 - 128

    

15. Genotyping the risk of anthracycline-induced cardiotoxicity

    • Shiwei Deng
    • Leszek Wojnowski

    Original Paper 19 April 2007 Pages: 129 - 134

16. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors

    • Jacques Robert

    Original Paper 17 April 2007 Pages: 135 - 139

    

17. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

    • Brian B. Hasinoff
    • Eugene H. Herman

    OriginalPaper 25 April 2007 Pages: 140 - 144

    

18. New iron chelators in anthracycline-induced cardiotoxicity

    • Helena Kaiserová
    • Tomáš Šimůnek
    • Aalt Bast

    Original Paper 19 April 2007 Pages: 145 - 150

    

19. Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries

    • Seppo W. Langer
    • Peter Buhl Jensen
    • Maxwell Sehested

    OriginalPaper 25 April 2007 Pages: 151 - 153

20. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials

    • Aalt Bast
    • Guido R. M. M. Haenen
    • Wim J. F. Van der Vijgh

    OriginalPaper Open access 26 May 2007 Pages: 154 - 159

    

21. Novel antioxidants in anthracycline cardiotoxicity

    • Kálmán Hideg
    • Tamás Kálai

    OriginalPaper 03 May 2007 Pages: 160 - 164